Page 1 | Search Results | Blood | American Society of Hematology

1-14 of 14

Sort by

Sort Order Select

Journal Articles

Nonclinical Toxicology, Biodistribution, and Pharmacokinetics of UB-VV111, an In Vivo Anti-CD19 CAR T Cell Therapy

Alissa H. Brandes, Angela Soo Min Koo, Anai Perez, Kathryn Michels, Travis Friesen, Alyssa Sheih, Don Parilla, Susana Hernandez, Nolan Ericson, Sarah Dickerson, Mason Muhonen, Jessica Freeman, Sarah Gould, Alessandra Maria Sullivan, Jeffrey Teoh, Byoung Y. Ryu, Andrew M. Scharenberg, Ryan P. Larson

Blood (2024) 144 (Supplement 1): 2046.

https://doi.org/10.1182/blood-2024-211032

Published: 2024

Journal Articles

Histone Methylation Mark Analyses Distinguish Carts Manufactured from Distinct Sources and Uncover Novel Transcription Factors Associated with In Vivo Function of Carts after Infusion into DLBCL Patients That Are Not Identified By RNA-Seq

Salvatore Fiorenza, Ye Zheng, Jay Sarthy, Alyssa Sheih, Erik L Kimble, Delaney Kirchmeier, Derek Janssens, Tinh-Doan Phi, Jordan Gauthier, Alexandre V Hirayama, Qian Wu, Raphael Gottardo, Stanley R. Riddell, David G Maloney, Steven Henikoff, Cameron J. Turtle

Blood (2023) 142 (Supplement 1): 3454.

https://doi.org/10.1182/blood-2023-188269

Published: 2023

Journal Articles

Long-Term Follow-up and Single-Cell Multiomics Characteristics of Infusion Products in Patients with Chronic Lymphocytic Leukemia Treated with CD19 CAR-T Cells

Alexandre V. Hirayama, Ye Zheng, Mark R. Dowling, Alyssa Sheih, Tinh-Doan Phi, Delaney R. Kirchmeier, Abby W. Chucka, Jordan Gauthier, David G. Maloney, Raphael Gottardo, Cameron J. Turtle

Blood (2021) 138 (Supplement 1): 1749.

https://doi.org/10.1182/blood-2021-151571

Published: 2021

Journal Articles

Recombinant CD19 Glycomutant Accurately and Reproducibly Detects CD19-Directed CAR-T Cells By Flow Cytometry

Delaney R. Kirchmeier, Alyssa Sheih, Salvatore Fiorenza, Alexandre V. Hirayama, Cassie Chou, Erik Kimble, Jordan Gauthier, Alison Williams, Jason Price, Colin Correnti, Cameron J. Turtle

Blood (2021) 138 (Supplement 1): 1724.

https://doi.org/10.1182/blood-2021-148229

Published: 2021

Journal Articles

Factors associated with outcomes after a second CD19-targeted CAR T-cell infusion for refractory B-cell malignancies

Blood (2021) 137 (3): 323–335.

https://doi.org/10.1182/blood.2020006770

Published: 2021

Includes: Supplemental data

Journal Articles

High IL-15 Serum Concentrations Are Associated with Response to CD19 CAR T-Cell Therapy and Robust In Vivo CAR T-Cell Kinetics

Jordan Gauthier, MD MSc, Cassie Chou, MDPhD, Alexandre V. Hirayama, MD, Salvatore Fiorenza, MBBS, PhD, Alyssa Sheih, PhD, Barbara S. Pender, MSc, Tinh-Doan Phi, BSc, Rachel Steinmetz, BSc, Abby Jamieson, BSc, Delaney R Kirchmeier, BSc, Henna N Di, BSc, Stanley R. Riddell, MD, David G. Maloney, MD PhD, Cameron J. Turtle, MBBS, PhD

Blood (2020) 136 (Supplement 1): 37–38.

https://doi.org/10.1182/blood-2020-140120

Published: 2020

Journal Articles

Feasibility and efficacy of CD19-targeted CAR T cells with concurrent ibrutinib for CLL after ibrutinib failure

Jordan Gauthier, Alexandre V. Hirayama, Janaki Purushe, Kevin A. Hay, James Lymp, Daniel H. Li, Cecilia C. S. Yeung, Alyssa Sheih, Barbara S. Pender, Reed M. Hawkins, Aesha Vakil, Tinh-Doan Phi, Rachel N. Steinmetz, Mazyar Shadman, Stanley R. Riddell, David G. Maloney, Cameron J. Turtle

Blood (2020) 135 (19): 1650–1660.

https://doi.org/10.1182/blood.2019002936

Published: 2020

Includes: Supplemental data

Journal Articles

Impact of Intestinal Microbiota on Reconstitution of Mucosal-Associated Invariant T Cells after Allogeneic Hematopoietic Stem Cell Transplantation

Alyssa Sheih, PhD, Jonathan L. Golob, MD, PhD, Abir Bhattacharyya, MBBS, Michael C. Wu, PhD, Aesha Vakil, MSc, Sujatha Srinivasan, PhD, Steven A. Pergam, MD MPH, David N. Fredricks, MD, Cameron J. Turtle, MBBS, PhD

Blood (2018) 132 (Supplement 1): 3393.

https://doi.org/10.1182/blood-2018-99-115158

Published: 2018

Journal Articles

Clonal Kinetics and Single Cell Transcriptional Profiling of Adoptively Transferred CD19 CAR-T Cells

Alyssa Sheih, PhD, Laila-Aicha Hanafi, PhD, Valentin Voillet, PhD, Hannah A. DeBerg, PhD, Reed M. Hawkins, BS, Masanao Yajima, PhD, Vivian Gersuk, PhD, Peter S. Linsley, PhD, Raphael Gottardo, PhD, Cameron J. Turtle, MBBS, PhD

Blood (2018) 132 (Supplement 1): 702.

https://doi.org/10.1182/blood-2018-99-111350

Published: 2018

Journal Articles

Immunotherapy with T-Cells Engineered with a Chimeric Antigen Receptor Bearing a Human CD19-Binding Single Chain Variable Fragment for Relapsed or Refractory Acute Lymphoblastic Leukemia and B-Cell Non-Hodgkin Lymphoma

Jordan Gauthier, MD, Alexandre V. Hirayama, MD, Kevin A. Hay, MDFRCPC, MSc, Alyssa Sheih, PhD, Barbara S. Pender, MSc, Reed M. Hawkins, BS, Aesha Vakil, MSc, Tinh-Doan Phi, BS, Rachel N. Steinmetz, BS, Aude G. Chapuis, MD, Brian G. Till, MD, Hans-Peter Kiem, MD PhD, Mazyar Shadman, Ryan D. Cassaday, MD, Utkarsh H. Acharya, DO, Stanley R. Riddell, MD, David G. Maloney, MD PhD, Cameron J. Turtle, MBBS, PhD

Blood (2018) 132 (Supplement 1): 1415.

https://doi.org/10.1182/blood-2018-99-111528

Published: 2018

Journal Articles

Efficacy and Toxicity of JCAR014 in Combination with Durvalumab for the Treatment of Patients with Relapsed/Refractory Aggressive B-Cell Non-Hodgkin Lymphoma

Blood (2018) 132 (Supplement 1): 1680.

https://doi.org/10.1182/blood-2018-99-116745

Published: 2018

Journal Articles

Factors Impacting Progression-Free Survival after CD19-Specific CAR-T Cell Therapy for Relapsed/Refractory Aggressive B-Cell Non-Hodgkin Lymphoma

Blood (2018) 132 (Supplement 1): 1681.

https://doi.org/10.1182/blood-2018-99-115126

Published: 2018

Journal Articles

Multivariable Modeling of Disease and Treatment Characteristics of Adults with B-ALL in MRD-Negative CR after CD19 CAR-T Cells Identifies Factors Impacting Disease-Free Survival

Blood (2018) 132 (Supplement 1): 281.

https://doi.org/10.1182/blood-2018-99-110561

Published: 2018

Journal Articles

Comparison of Efficacy and Toxicity of CD19-Specific Chimeric Antigen Receptor T-Cells Alone or in Combination with Ibrutinib for Relapsed and/or Refractory CLL

Blood (2018) 132 (Supplement 1): 299.

https://doi.org/10.1182/blood-2018-99-111061

Published: 2018

NARROW

Nonclinical Toxicology, Biodistribution, and Pharmacokinetics of UB-VV111, an In Vivo Anti-CD19 CAR T Cell Therapy

Histone Methylation Mark Analyses Distinguish Carts Manufactured from Distinct Sources and Uncover Novel Transcription Factors Associated with In Vivo Function of Carts after Infusion into DLBCL Patients That Are Not Identified By RNA-Seq

Long-Term Follow-up and Single-Cell Multiomics Characteristics of Infusion Products in Patients with Chronic Lymphocytic Leukemia Treated with CD19 CAR-T Cells

Recombinant CD19 Glycomutant Accurately and Reproducibly Detects CD19-Directed CAR-T Cells By Flow Cytometry

Factors associated with outcomes after a second CD19-targeted CAR T-cell infusion for refractory B-cell malignancies

High IL-15 Serum Concentrations Are Associated with Response to CD19 CAR T-Cell Therapy and Robust In Vivo CAR T-Cell Kinetics

Feasibility and efficacy of CD19-targeted CAR T cells with concurrent ibrutinib for CLL after ibrutinib failure

Impact of Intestinal Microbiota on Reconstitution of Mucosal-Associated Invariant T Cells after Allogeneic Hematopoietic Stem Cell Transplantation

Clonal Kinetics and Single Cell Transcriptional Profiling of Adoptively Transferred CD19 CAR-T Cells

Immunotherapy with T-Cells Engineered with a Chimeric Antigen Receptor Bearing a Human CD19-Binding Single Chain Variable Fragment for Relapsed or Refractory Acute Lymphoblastic Leukemia and B-Cell Non-Hodgkin Lymphoma

Efficacy and Toxicity of JCAR014 in Combination with Durvalumab for the Treatment of Patients with Relapsed/Refractory Aggressive B-Cell Non-Hodgkin Lymphoma

Factors Impacting Progression-Free Survival after CD19-Specific CAR-T Cell Therapy for Relapsed/Refractory Aggressive B-Cell Non-Hodgkin Lymphoma

Multivariable Modeling of Disease and Treatment Characteristics of Adults with B-ALL in MRD-Negative CR after CD19 CAR-T Cells Identifies Factors Impacting Disease-Free Survival

Comparison of Efficacy and Toxicity of CD19-Specific Chimeric Antigen Receptor T-Cells Alone or in Combination with Ibrutinib for Relapsed and/or Refractory CLL

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only